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Background 
Economic evaluation has increasingly become an integral component of Randomised Controlled Trial 
(RCT) designs. UK organisations, such as the National Institute for Health Research’s Health 
Technology Assessment (NIHR HTA) Programme and the Medical Research Council, fund RCTs that try 
to address both clinical effectiveness issues as well as cost-effectiveness considerations. The proposed 
economic evaluation is outlined in the application, and once a proposal is funded, a section in the 
protocol may describe the intended analysis to be followed as part of the economic evaluation based 
on the RCT. Guidance on how to conduct economic evaluation alongside RCTs has been published 
elsewhere [1] together with considerations around methodological issues and the novel approaches 
that may be applied [2].  
A guidance document (known as a Standard Operating Procedure) that outlines the predetermined 
steps and instructions to be followed as part of the economic as well as the statistical analysis of a trial 
is an important aspect of the quality management of any trial. In a way, it safeguards the transparency 
and consistency of the higher level steps that should be followed as part of any analysis. 
However, little is known to date about how to integrate health economics operating procedures, and 
health economics analysis plans (HEAPs) as part of a study. Common questions arising are i) Is a HEAP 
always needed? ii) What information should be included as standard? iii) Can a proposed HEAP be 
changed, and if so, in what circumstances?   
Before answering these very important questions, we took a step back to first identify current practice 
and opinions about the use of HEAPs and HEAP Standard Operating Procedures (SOPs). We expected 
a-priori that Clinical Trials Units (CTUs) and individual health economists would follow specific 
instructions about who should write and approve a HEAP, for whom, and when as well as the types of 
RCTs for which a HEAP is necessary.  
 
Methods 
Six health economists and one statistician from the Universities of Oxford, Warwick and Bristol, under 
the umbrella of the MRC Network of Hubs for Trials Methodology Research, were involved in the 
design of an electronic survey targeting registered UK Clinical Trial Units (http://www.ukcrc-
ctu.org.uk/). 
For the purpose of the survey a HEAP was defined as: “a document which provides details on the 
economic analysis to be followed as part of a trial.  The final report and any subsequent analysis should 
follow the main principles outlined in the HEAP. Any deviations from the HEAP should be described and 
justified in the final report of the trial”. A HEAP Standard Operating Procedure (SOP): “describes the 
procedure for the development and utilisation of a HEAP for Clinical Research. The SOP does not 
address the use of specific health economics procedures or methods, but rather outlines all important 
details of the design and conduct of the clinical research and the principle features of its proposed 
economic analysis, to avoid post-hoc decisions that may affect the credibility and interpretation of the 
economic analysis”. Both definitions were discussed with all individuals involved in the design of the 
survey with disagreements resolved through consensus.  
The survey was tested amongst health economists, clinicians and statisticians, with a few changes 
made to improve stratification of some of the available replies, before being expanded to the full set 
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of CTUs with the web-based survey link live for two months (April/May 2017). Health economists 
named as collaborators with CTUs were identified though each CTU’s website, and were the primary 
target group for the survey. If health economists were not identified, then the lead statistician was 
contacted and if no health economist or statisticians were named on the CTU website, then the CTU 
director was approached. Study participants were recruited by email. 
The survey asked for each participant’s name, the CTU or organisation they belonged to and their job 
title, and was therefore not anonymous. Participants were asked among other questions if they had a 
health economics team embedded (i.e. employed staff) within their CTU, if the RCTs run by the CTU 
had HEAPs and if their CTU had a HEAP SOP or instructions in place (the detailed questionnaire can be 
found in the Appendix). None of the questions were mandatory.  
 
Results 
From the original 46 UK fully registered CTUs contacted, six CTUs identified a common health 
economist (three pairs of CTUs employing the same health economist) and another four did not have 
available contact information. 
From the 39 remaining CTUs our response rate was 72% (28/39).  The majority of respondents were 
health economists (71%), followed by statisticians (21%) and heads of operations or co-directors (4%), 
respectively. Table 1 presents details of responses to each survey question. 
Only 39 % (11/28) of the respondents reported a health economics team embedded within their CTUs,  
29% do not have  health economics teams embedded within their units, but  work closely with external 
health economics teams, and a further 32% employed other arrangements. In terms of HEAPs and 
HEAP SOPs, our survey suggests that one third of CTUs always have a HEAP in place, whereas only 37 
% of them have HEAP SOPs or broader instructions in place. In terms of type of study, full RCTs and 
publicly funded RCTs were more likely to always have a HEAP (57% and 43%, respectively). Health 
economists, regardless of seniority level, were the major contributors to drafting a HEAP, as expected. 
Study chief investigators were less involved (52%) in writing up the HEAP, and statisticians were the 
least likely to be the main contributors (19%). In terms of HEAP approval and signing off, the chief 
investigator and the internal senior health economist were the main contributors.  When we asked 
participants to state from the selected options for whom they think a HEAP is written, with multiple 
responses permitted, the largest proportion selected health economists (93%), followed by the chief 
investigator (85%), Trial Management Group members and Trial Steering Committee members (74% 
respectively), the chief statistician (70%), the funder (59%), Data Monitoring and Ethics Committee 
members (48%) and others (7%). Finally, with regards to the best time to produce a HEAP, more than 
one half of the participants (54%) agreed it should be any time before the database is locked and final 
analysis begins. 
 
Discussion 
As the number of clinical trials with health economic endpoints continues to grow, a standardised 
approach towards analysis and reporting of results [3] becomes imperative for ensuring transparency 
and replicability of the results [4]. 
A proposal to standardise operating procedure for HEAPs was published back in 2008 by a team of 
health economists at Bangor University [5]. Our survey suggests that only one third of the UK based 
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CTUs have HEAP instructions in place, and that these are largely for internal use only. Around 30% of 
CTUs write HEAPs as a standard practice. The lack of consistency concerning the people who are 
involved in writing up and signing off the analysis plan, the intended audience and the timing of writing 
a HEAP, all contribute to an inconsistent approach towards HEAPs.  
A potential limitation of our survey is the variability in the interpretation of our findings with respect 
to the definition of some of the predefined categories. More specifically, “always” is interpreted as 
100% of the time, whereas “sometimes” could range from 1-99% of the times. That makes it difficult 
for some of the survey answers to be strictly quantifiable.  
Conclusion 
Owing to respondents’ lack of consensus about their own approach or their unit’s approach towards 
economic analysis within RCTs,  we suggest that all registered UK CTUs would benefit from guidelines 
and instructions for the development of HEAPs and HEAP SOPs. A systematic and transparent 
approach should be followed to develop Health Economic Analysis Plans to complement trial 
protocols,  which should enhance the reproducibility of the data analysis and also the overall quality 
management of the trial.  
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Table 1.  Survey results (n=28) 
Question  Frequency % 
Do you have a health 
economics team embedded 
within your CTU? 
Yes 11 39.29 
No 8 28.57 
Other 9 32.14 
Do the RCTs run by your 
CTU have HEAPs? 
Always 8 29.63 
Sometimes 16 59.26 
Never 1 3.7 
Not required 0 0.00 
N/A 2 7.41 
Does your CTU have a HEAP 
SOP or instructions in 
place? 
Yes 10 37.04 
No 17 62.96 
How often does your CTU 
write HEAPs for phase III 
trials? 
Always 9 34.62 
sometimes 10 38.46 
never 2 7.69 
N/A 5 19.23 
How often does your CTU 
write HEAPs for phase IV 
trials? 
Always 7 25.93 
sometimes 9 33.33 
never 3 11.11 
N/A 8 29.63 
How often does your CTU 
write HEAPs for pilot RCTs? 
Always 6 22.22 
sometimes 9 33.33 
never 7 25.93 
N/A 5 18.52 
How often does your CTU 
write HEAPs for full RCTs? 
Always 16 57.14 
sometimes 5 17.86 
never 3 10.71 
N/A 4 14.29 
How often does your CTU 
write HEAPs for 
commercially funded RCTs? 
Always 2 7.41 
sometimes 3 11.11 
never 3 11.11 
N/A 19 70.37 
How often does your CTU 
write HEAPs for publicly 
funded RCTs? 
Always 12 42.86 
sometimes 9 32.14 
never 3 10.71 
N/A 4 14.29 
Who is the intended 
audience of a HEAP?  
(can select >1) 
Health economists 25 92.59 
statisticians 19 70.37 
chief investigator 23 85.19 
trials management group 20 74.07 
DMEC members 13 48.15 
TSC members 20 74.07 
funder-regulator 16 59.26 
other  2 7.41 
Before recruitment begins  4 15.38 
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When is a HEAP normally 
written and signed off? 
before recruitment ends 6 23.08 
any time before the database is 
locked and final analysis begins 
14 53.85 
other  2 7.69 
Who is involved in drafting 
the HEAP?  
(can select >1) 
Junior health economist 
 
22 81.48 
senior health economist 25 92.59 
statistician 5 18.52 
chief investigator 14 51.85 
other  2 7.41 
Who approves and signs off 
the HEAP?  
(can select >1) 
Chief investigator 21 77.78 
statistician 6 22.22 
senior health economist-internal 20 74.07 
senior health economist- externa 6 22.22 
DMEC-TSC members 4 14.81 
other  7 25.93 
If you do have a HEAP 
and/or HEAP SOPs would 
you be happy to share it 
with us for the purpose of 
facilitating this piece of 
research? 
Yes 10 37.04 
no, we don’t have a HEAP in our 
CTU 
5 18.52 
no, we don’t have a HEAP SOP in 
our CTU 
10 37.04 
other reason  11 40.74 
 
 
Appendix 
Questions for the Health Economics Analysis Plans Survey 
 
 Questions Possible answers 
Q1 Could you please state you name? Open question 
Q2 What is the name of the Clinical trials unit (CTU) 
you primarily work with? 
Open question 
Q3 Could you please describe your job title in the 
CTU? 
Open question 
Q4 Do you have a health economics team embedded 
within your CTU? 
Yes/ No, but we collaborate with 
external health economics groups/ 
please state any other 
arrangements 
Q5 Do the RCTs run by your CTU have HEAPs? Always/sometimes/never/not 
required/non -applicable 
Q6 Does your CTU have a HEAP SOP or instructions in 
place? 
Yes/no 
Q7 How often does your CTU write HEAPs for phase 
III trials? 
Always/sometimes/never/non-
applicable (our CTU does not 
undertake health economics on 
these trials) 
Q8 How often does your CTU write HEAPs for phase 
IV trials? 
Always/ sometimes/never/non-
applicable (our CTU does not 
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undertake health economics on 
these trials) 
Q9 How often does your CTU write HEAPs for pilot 
RCTs? 
Always/ sometimes/never/non-
applicable (our CTU does not 
undertake health economics on 
these trials) 
Q10 How often does your CTU write HEAPs for full 
RCTs? 
Always/ sometimes/never/non-
applicable (our CTU does not 
undertake health economics on 
these trials) 
Q11 How often does your CTU write HEAPs for 
commercially funded RCTs? 
Always/sometimes/ never/ non-
applicable 
Q12 How often does your CTU write HEAPs for 
publicly funded RCTs? 
Always/sometimes/ never/ non-
applicable 
Q13 Who is the intended audience of a HEAP?  
(can select >1) 
Health economists/ statisticians/ 
chief investigator/ trials 
management group/ DMEC 
members/ TSC members/ funder-
regulator/ other (please specify) 
Q14 When is a HEAP normally written and signed off? Before recruitment begins/ before 
recruitment ends/ any time before 
the database is locked and final 
analysis begins/ other (please 
specify) 
Q15 Who is involved in drafting the HEAP?  
(can select >1) 
Junior health economist/ senior 
health economist/ statistician/ chief 
investigator/ other (please specify) 
Q16 Who approves and signs off the HEAP?  
(can select >1) 
Chief investigator/ statistician/ 
senior health economist-internal/ 
senior health economist- external/ 
DMEC-TSC members/ other (please 
specify) 
Q17 If you do have a HEAP and/or HEAP SOPs would 
you be happy to share it with us for the purpose 
of facilitating this piece of research? 
Yes/ no, we don’t have a HEAP in 
our CTU/ no, we don’t have a HEAP 
SOP in our CTU/ other reason 
(please specify) 
 
